Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Daiichi Sankyo
Farmers Insurance
McKinsey
Mallinckrodt
Baxter

Generated: May 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,737,142

« Back to Dashboard

Which drugs does patent 7,737,142 protect, and when does it expire?

Patent 7,737,142 protects VRAYLAR and is included in one NDA.

This patent has forty-five patent family members in thirty-four countries.

Summary for Patent: 7,737,142
Title:(Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists
Abstract: The present invention relates to new D3 and D2 dopamine receptor subtype preferring ligands of formula (I): ##STR00001## wherein R.sub.1 and R.sub.2 represent independently a substituent selected from hydrogen, alkyl, aryl, cycloalkyl, aroyl, or R.sub.1 and R.sub.2 may form a heterocyclic ring with the adjacent nitrogen atom; X represents an oxygen or sulphur atom; n is an integer of from 1 to 2, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof, to the processes for producing the same, to pharmaceutical compositions containing the same and to their use in therapy and/or prevention of a condition which requires modulation of dopamine receptors.
Inventor(s): Againe Csongor; Eva (Budapest, HU), Galambos; Janos (Budapest, HU), Nogradi; Katalin (Budapest, HU), Vago; Istvan (Budapest, HU), Gyertyan; Istvan (Budapest, HU), Kiss; Bela (Budapest, HU), Laszlovszky; Istvan (Budapest, HU), Laszy; Judit (Nagykovacsi, HU), Saghy; Katalin (Budapest, HU)
Assignee: Richter Gedeon Vegyeszeti Gyar Rt. (Budapest, HU)
Application Number:11/337,275
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,737,142
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Drugs Protected by US Patent 7,737,142

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan Sales Llc VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370-001 Sep 17, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF SCHIZOPHRENIA AND/OR ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE ➤ Sign Up
Allergan Sales Llc VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370-002 Sep 17, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF SCHIZOPHRENIA AND/OR ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE ➤ Sign Up
Allergan Sales Llc VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370-003 Sep 17, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF SCHIZOPHRENIA AND/OR ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,737,142

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
HungaryP0302451Aug 4, 2003

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
UBS
Daiichi Sankyo
Boehringer Ingelheim
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.